Lava signs collaboration agreement with MSD for prostate cancer therapy
MSD will supply Keytruda to be evaluated as a combination treatment with Lava’s LAVA-1207 in an ongoing Phase I/IIa study.
MSD will supply Keytruda to be evaluated as a combination treatment with Lava’s LAVA-1207 in an ongoing Phase I/IIa study.
What's Your Reaction?
